Publications by authors named "D M Mandracchia"
Article Synopsis
- Curcumin (Cur) and resveratrol (Rsv) have potential uses in both anti-tumor and wound healing treatments, and their effects on blood vessel formation (angiogenesis) can vary based on the intended application.
- This study compared electrospun fibers made from collagen and polycaprolactone (PCL) loaded with Cur and Rsv, finding that Rsv-loaded fibers were larger and had better wettability.
- Results showed both types of fibers were biocompatible, leading to an increase in fibroblast cells, and both exhibited anti-angiogenic properties, indicating a stronger suitability for anti-cancer applications rather than wound healing.
Article Synopsis
- Identifying how radioresistance works in rhabdomyosarcoma (RMS), a type of pediatric tumor, is crucial for better treatment strategies.
- Researchers observed that radiation therapy increases the activity of key proteins (Akt1, Src, Cav1) that help cells resist damage and survive.
- Using cholesterol-lowering drugs (statins) can enhance cell death in RMS by boosting oxidative stress, which could improve the effectiveness of radiotherapy when combined with certain treatments.
Article Synopsis
- * The development of targeted liposomes for cancer therapy has faced challenges, but a new type called Super Stealth Immunoliposomes (SSIL2) shows promise by stabilizing the protective polymer layer and effectively targeting cancer cells.
- * Experimental results indicate that SSIL2 outperforms traditional stealth liposomes and stealth immunoliposomes in both safety and anticancer efficacy during tests in cell cultures, zebrafish larvae, and rodent models, marking progress in targeted cancer treatment.
In pediatric rhabdomyosarcoma (RMS), elevated Akt signaling is associated with increased malignancy. Here, we report that expression of a constitutively active, myristoylated form of Akt1 (myrAkt1) in human RMS RD cells led to hyperactivation of the mammalian target of rapamycin (mTOR)/70-kDa ribosomal protein S6 kinase (p70S6K) pathway, resulting in the loss of both MyoD and myogenic capacity, and an increase of Ki67 expression due to high cell mitosis. MyrAkt1 signaling increased migratory and invasive cell traits, as detected by wound healing, zymography, and xenograft zebrafish assays, and promoted repair of DNA damage after radiotherapy and doxorubicin treatments, as revealed by nuclear detection of phosphorylated H2A histone family member X (γH2AX) through activation of DNA-dependent protein kinase (DNA-PK).
View Article and Find Full Text PDFArticle Synopsis
- The study focuses on developing a pharmaceutical product from mesenchymal stem cell (MSC) secretome, specifically a formulation called lyosecretome, using GMP-compliant procedures for scalability and consistency.
- Key objectives include optimizing the lyosecretome formulation, addressing variability in the manufacturing process, and adjusting ultrafiltration to standardize the final product for clinical use.
- Results indicate that using a maximum concentration of excipients preserves protein and lipid content better, while the secretome batch was identified as a major variability source; modifications led to a more reproducible product with enhanced biological activity.